European Journal of Cancer
Volume 46, Issue 8 , Pages 1430-1437 , May 2010

Loss of expression of TIMP3 in clear cell renal cell carcinoma

  • Damien Masson

      Affiliations

    • CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France
    • INSERM U913, Institut des Maladies de l’appareil digestif, CHU Nantes, 44035 Nantes, France
    • ,
  • Nathalie Rioux-Leclercq

      Affiliations

    • CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France
    • ,
  • Patricia Fergelot

      Affiliations

    • CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France
    • ,
  • Florence Jouan

      Affiliations

    • CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France
    • ,
  • Stéphanie Mottier

      Affiliations

    • CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France
    • ,
  • Sandrine Théoleyre

      Affiliations

    • CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France
    • ,
  • Kalyane Bach-Ngohou

      Affiliations

    • INSERM U913, Institut des Maladies de l’appareil digestif, CHU Nantes, 44035 Nantes, France
    • ,
  • Jean-Jacques Patard

      Affiliations

    • CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France
    • ,
  • Marc G. Denis

      Affiliations

    • CNRS UMR 6061, Institut de Génétique et Développement, Université Rennes 1, 35043 Rennes, France
    • Corresponding Author InformationCorresponding author. Address: INSERM U913, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes cedex, France. Tel.: +33 240 41 29 59; fax: +33 240 08 39 91.

Received 1 July 2009 ,Revised 30 December 2009 ,Accepted 14 January 2010.

References 

  1. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–133
  2. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science. 1993;260:1317–1320
  3. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988;332:268–269
  4. Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez F, et al. VHL protein alterations in sporadic renal cell carcinoma. Clin Oncol. 2007;19:784–789
  5. Smits KM, Schouten LJ, van Dijk BA, et al. Genetic and epigenetic alterations in the von hippel–lindau gene: the influence on renal cancer prognosis. Clin Cancer Res. 2008;14:782–787
  6. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991–5004
  7. Kim JH, Jung CW, Cho YH, et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep. 2005;13:859–864
  8. Cockman ME, Masson N, Mole DR, et al. Hypoxia Inducible Factor-alpha binding and ubiquitylation by the von Hippel–Lindau tumor suppressor protein. J Biol Chem. 2000;275:25733–25741
  9. Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel–Lindau gene status. BJU Int. 2006;98:756–762
  10. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  11. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992;187:1579–1586
  12. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA. 1993;90:7533–7537
  13. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9:407–415
  14. Apte SS, Mattei MG, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics. 1994;19:86–90
  15. Lui EL, Loo WT, Zhu L, Cheung MN, Chow LW. DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma. Biomed Pharmacother. 2005;59:S363–S365
  16. Liu MC, Choong DY, Hooi CS, Williams LH, Campbell IG. Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer. Cancer Lett. 2007;247:91–97
  17. Fendrich V, Slater EP, Heinmoller E, et al. Alterations of the tissue inhibitor of metalloproteinase-3 (TIMP3) gene in pancreatic adenocarcinomas. Pancreas. 2005;30:e40–e45
  18. Brueckl WM, Grombach J, Wein A, et al. Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI). Cancer Lett. 2005;223:137–142
  19. Blanchot-jossic F, Jarry A, Masson D, et al. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol. 2005;207:156–163
  20. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57
  21. Qureshi HY, Ahmad R, Sylvester J, Zafarullah M. Requirement of phosphatidylinositol 3-kinase/Akt signaling pathway for regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in human chondrocytes. Cell Signal. 2007;19:1643–1651
  22. Baldewijns MM, Thijssen VL, Van den Eynden GG, et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer. 2007;96:1888–1895
  23. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999;59:798–802
  24. Lau LC, Tan PH, Chong TW, Foo KT, Yip S. Cytogenetic alterations in renal tumors: a study of 38 Southeast Asian patients. Cancer Genet Cytogenet. 2007;175:1–7
  25. Copland JA, Luxon BA, Ajani L, et al. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene. 2003;22:8053–8062
  26. Zhao H, Shiina H, Greene KL, et al. CpG methylation at promoter site-140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer. 2005;104:44–52
  27. Myeroff LL, Parsons R, Kim SJ, et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995;55:5545–5547
  28. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336–1338
  29. Miyajima A, Asano T, Seta K, Kakoi N, Hayakawa M. Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology. 2003;61:1072–1077
  30. Parker AS, Lohse CM, Wu K, et al. Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. Hum Pathol. 2007;38:453–461
  31. Bian J, Wang Y, Smith MR, et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis. 1996;17:1805–1811
  32. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999;79:1347–1355

PII: S0959-8049(10)00028-6

doi: 10.1016/j.ejca.2010.01.009

European Journal of Cancer
Volume 46, Issue 8 , Pages 1430-1437 , May 2010

Article Tools

* Image Usage & Resolution